Related Experiment Video
Updated: Aug 14, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
ADAM proteases, ErbB pathways and cancer
Bin-Bing S Zhou1, Jordan S Fridman, Xiangdong Liu
1Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. bzhou@incyte.com
Abstract:
A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway is a validated target for anti-cancer drugs, the upstream activators of ErbB ligands, their sheddases, now enter the spotlight as new drug targets in the ErbB pathway. ADAMs are involved not only in tumour cell proliferation but also in angiogenesis and metastasis. Therefore, strategies targeting ADAMs might be an important complement to existing anti-ErbB approaches.
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

